Evidence map›Paper›PMID 39358863›Full record

ArticleESC heart failure2025

Gender-specific risks for incident cancer in patients with different heart failure phenotypes.

Qin-Fen Chen, Christos S Katsouras, Chenyang Liu, Jingjing Shi, Xiaoqian Luan, Chao Ni, Hongxia Yao, Yingdan Lu, Wei-Hong Lin, Xiao-Dong Zhou

Abstract read
In one paragraph

Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Tumour necrosis factor-Frontiers in nutrition · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qin-Fen ChenMedical Care Center, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Christos S KatsourasFirst Department of Cardiology, University Hospital of Ioannina Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Chenyang LiuDepartment of Cardiovascular Medicine, the Heart Center, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Jingjing ShiWenzhou Medical University Renji College, Wenzhou, China.
Xiaoqian LuanInstitute of Aging, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Zhejiang Provincial Clinical Research Center for Mental Disorders, Wenzhou Medical University, Wenzhou, China.
Chao NiInstitute of Aging, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Zhejiang Provincial Clinical Research Center for Mental Disorders, Wenzhou Medical University, Wenzhou, China.
Hongxia YaoDepartment of Cardiovascular Medicine, the Heart Center, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yingdan LuDepartment of Cardiovascular Medicine, the Heart Center, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Wei-Hong LinMedical Care Center, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Xiao-Dong ZhouDepartment of Cardiovascular Medicine, the Heart Center, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.ORCID https://orcid.org/0000-0002-8534-0818

Funding

Wenzhou Science Technology Bureau Foundation 2022Y0726Wenzhou Science Technology Bureau Foundation Y20210036
6 · The paper itself

Abstract

backgroundThere is conflicting evidence regarding whether heart failure (HF) increases the risk of developing cancer.

objectiveThis study aimed to assess the association between HF and incident cancer, considering gender differences and HF phenotypes.

methodsThis retrospective study was conducted on data of adult individuals, free of cancer at baseline, from the First Affiliated Hospital of Wenzhou Medical University between January 2009 and February 2023. The patients with HF were categorized as HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF). The primary outcome was incident cancer, including obesity-related, tobacco-related, lung, colorectal and breast cancers.

resultsOf 33 033 individuals enrolled, 16 722 were diagnosed with HF, including 10 086 (60.3%) with HFpEF and 6636 (39.7%) with HFrEF. During a median follow-up period of 4.6 years (inter-quartile range: 2.6-7.3), incident cancer was diagnosed in 10.5% (1707 patients) of the non-HF group and 15.1% (2533 individuals) of the HF group. After adjusting for potential confounding factors, patients with HF had a 58% increased risk of cancer than those without HF [adjusted hazard ratio (HR) 1.58, 95% confidence interval (CI) 1.48-1.69, P < 0.001]. This risk was consistent across genders (female: adjusted HR 1.95, 95% CI 1.74-2.18, P < 0.001; male: adjusted HR 1.41, 95% CI 1.30-1.54, P < 0.001) and HF phenotypes (HFpEF: adjusted HR 1.69, 95% CI 1.57-1.81, P < 0.001; HFrEF: adjusted HR 1.32, 95% CI 1.20-1.46, P < 0.001).

conclusionsBoth HFpEF and HFrEF are associated with an increased risk of incident cancer. This correlation maintains its validity across genders.

Indexed as

Heart FailureNeoplasmsStroke VolumeAgedChinaFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedPhenotypeRetrospective StudiesRisk AssessmentRisk FactorsSex Factorscancercardio‐oncologyheart failureheart failure with preserved ejection fractionheart failure with reduced ejection fractionprognosis

Identifiers

PMID39358863
PMCPMC11769628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.